TheraRadar
← Back
Data updated: Mar 29, 2026

MALLINCKRODT

GastroenterologyDermatologyMetabolic
Specialty

MALLINCKRODT is a specialty pharmaceutical company focused on Gastroenterology, Dermatology, Metabolic. Key products include XARTEMIS XR.

1947
Since
35
Drugs
-
Trials
349
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Competitive Matchups Pro

Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Gastroenterology 42%
0 drugs Phase 3: 1 Phase 2: 1 Phase 1: 2
Dermatology 32%
0 drugs Phase 3: 1 Phase 2: 1
Metabolic 11%
0 drugs Phase 1: 2
Immunology 11%
0 drugs Phase 1: 2
Respiratory 5%
0 drugs Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...